The FDA no longer expects prescribers, pharmacies, and patients to participate in the risk evaluation and mitigation strategy (REMS) program for the antipsychotic clozapine, the agency announced this ...
FRIDAY, Feb. 28, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has removed one hurdle faced by patients with schizophrenia when filling prescriptions for the antipsychotic medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback